Status:
COMPLETED
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Defining Which Remission Criterion at Month 6 Predicts Remission at Month 12 in a Real Life Clinical Practice, in a Cohort of Rheumatoid Arthritis Patients Treated with Etanercept
Detailed Description
The analysis of the primary endpoint will be based on a logistic regression defining the dependent variable as the remission at Month 12 and the 5 independent variables as CDAI, SDAI, DAS28, DAS28 and...
Eligibility Criteria
Inclusion
- Patients with active RA who start treatment with etanercept according to the prevailing reimbursement criteria and dosing in line with the SmPC.
- First cohort: Etanercept is the first biological product prescribed.
- Second cohort: Etanercept is the second biological product prescribed.
- Capable of understanding and willing to provide signed and dated written, voluntary informed consent before any protocol-specific procedures are performed.
- Eighteen (18) years of age or older at time of consent.
Exclusion
- 1\. History of or current psychiatric illness that would interfere with the subject's ability to comply with protocol requirements or to give informed consent.
Key Trial Info
Start Date :
August 12 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 24 2017
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT02202837
Start Date
August 12 2014
End Date
April 24 2017
Last Update
December 3 2018
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Dinant Godinne
Yvoir, Namur, Belgium, 5530
2
ASZ Aalst
Aalst, Belgium, 9300
3
Algemeen Stedelijk Ziekenhuis
Aalst, Belgium, B-9300
4
Onze Lieve Vrouw Ziekenhuis Aalst
Aalst, Belgium, B-9300